Boehringer Ingelheim Exercised its Option to License Oxford Biomedica’s Lentiviral Vector Technology to Commercialize BI 3720931 for CF
Shots: OXB to receive $4.83M as an option exercise fee & ~$37.96M in development, regulatory & sales milestones along with royalty on sales of a […]